European Heart Journal vs Blood: Which Journal Should You Choose?

EHJ asks whether the result matters across cardiology. Blood asks whether the result matters across hematology.

That distinction is more useful than any prestige comparison.

EHJ's editorial guidance keep returning to field-wide cardiovascular significance, practice consequence, and general cardiology readership. Blood's editorial guidance keep returning to broad hematology relevance, complete mechanistic stories, and work that matters beyond one narrow disease or assay niche.

So if your paper becomes stronger when written as a general cardiology manuscript, EHJ is more realistic. If it becomes stronger when written for hematologists, Blood is more realistic.

EHJ wins when the cardiovascular story dominates.

That usually means:

• the main consequence is about cardiovascular outcomes, risk, or management
• the practical audience is cardiologists
• the hematologic context matters, but the core message still lives in cardiology
• the paper belongs in a broad cardiovascular conversation rather than a hematology conversation

Examples:

• thrombosis studies where the real implication is cardiovascular management
• cardio-oncology or coagulation papers where the result should change how cardiologists interpret treatment risk
• cardiovascular-outcome work in hematologic populations when the core consequence isn't disease-specific hematology practice

Blood wins when the hematology story dominates.

That includes:

• coagulation and platelet papers that matter broadly to hematologists
• translational blood-disease studies with clear hematologic consequence
• hematologic malignancy or blood-disorder papers where cardiovascular findings are important, but still secondary
• mechanistic or clinical blood research where the real readership is inside hematology

Blood's editorial guidance are especially clear that the journal wants research about blood cells or hematologic disorders, not general biology or general medicine that happens to touch blood.

Blood submission's editorial guidance emphasizes complete mechanistic stories, functional validation, and manuscripts that close meaningful hematology questions rather than merely opening them.

EHJ's editorial guidance make clear that narrow specialist stories, even strong ones, struggle if they don't matter across cardiology.

A thrombosis or coagulation paper isn't automatically a Blood paper. The result still has to contribute to hematology, not only to cardiovascular management.

The fact that a study is biologically rich or hematologically important doesn't by itself make it suitable for a broad cardiology flagship.

• the manuscript is fundamentally cardiovascular
• cardiologists are the main audience
• the main implication is cardiovascular interpretation, prevention, or management
• the paper feels strongest as a cardiology paper

That's the EHJ lane.

• the manuscript is fundamentally hematologic
• hematologists are the main audience
• the work matters broadly across blood biology or hematologic disease
• the paper feels strongest as a hematology paper

That's the Blood lane.

These are the most obvious overlap zone. If the paper is mainly about cardiovascular management or cardiology-facing decision-making, EHJ can make sense. If the paper is mainly about coagulation biology, thrombosis mechanisms, or broad hematology consequence, Blood is often more natural.

Again, the question isn't whether both fields care. It's which field has to act first. If the paper changes hematology interpretation, Blood gets stronger. If it changes cardiology practice more broadly, EHJ becomes more realistic.

Some of these papers can go either way. The audience test still decides it. If the main message is how hematology or oncology teams should think about treatment consequences, Blood is more plausible. If the main message is how cardiologists should manage risk and outcomes, EHJ is more plausible.

This can be a real cascade, but only when the audience was wrong.

A paper rejected by EHJ can move to Blood if:

• the work is genuinely hematology-led
• the rejection reflected insufficient breadth for cardiology
• the manuscript is still strong enough for a flagship hematology journal

The reverse route is less common. A paper rejected by Blood because it lacks enough hematologic relevance doesn't usually become an EHJ paper unless the cardiovascular consequence was the real center of gravity all along.

If the paper only feels important once the reader is already inside a hematology problem, EHJ often becomes the wrong room.

Blood's editorial guidance make clear that papers using blood cells or coagulation as a convenient model don't fit well unless the work truly answers a hematologic question.

If the manuscript's claim to broad cardiology importance feels inflated, that usually shows quickly.

Especially in basic and translational work, the journal wants completeness, not just interesting directionality.

A strong EHJ first page tells a cardiology editor why the result matters across cardiovascular medicine before specialty detail takes over.

A strong Blood first page tells a hematology editor why the result matters broadly across hematology before the cardiovascular crossover angle takes over.

If only one of those openings feels natural, that's usually the better journal.

Try finishing one of these sentences:

• "this changes what cardiologists should do or how they stratify cardiovascular risk" points toward European Heart Journal
• "this changes what hematologists should do or how they interpret blood disease biology" points toward Blood

That sentence test is simple, but it's often enough.

Some authors assume that any thrombosis, coagulation, or cardio-oncology manuscript automatically belongs in whichever journal has the higher cardiovascular profile. That isn't how editors read these papers.

A good Blood paper can be deeply important without being a general cardiology paper. A good EHJ paper can involve blood biology or coagulation without being a hematology paper. Once you see that difference clearly, the targeting decision usually gets much easier.

Send to European Heart Journal first if:

1. the manuscript is fundamentally cardiovascular
2. cardiologists are the practical audience
3. the paper has broad cardiovascular consequence
4. the hematologic context supports the story, but doesn't define it

Send to Blood first if:

1. the manuscript is fundamentally hematologic
2. hematologists are the practical audience
3. the paper matters broadly across hematology
4. cardiovascular findings are important, but still inside a blood-disease or coagulation story

Submit to European Heart Journal first if:

• The manuscript is fundamentally cardiovascular: cardiac arrhythmias triggered by hematologic disease, cardiovascular outcomes research where blood disorders are the exposure, or imaging or biomarker work that cardiologists must act on
• ESC-facing cardiovascular practice or broad cardiology consequence is central to the paper's significance
• Cardiologists are the primary clinical audience who need the result to change their practice

Think twice about EHJ if:

• The paper's primary mechanism, endpoints, and readership are hematological; EHJ editors will see that the paper belongs in a blood journal and the desk rejection is typically fast
• The thrombosis or coagulation story is mechanistic and does not have a clear cardiovascular practice arm; that is Blood or Journal of Thrombosis and Haemostasis territory
• You are submitting to EHJ because the impact factor is appealing rather than because cardiology is the right readership; field mismatch is a fast desk rejection

Submit to Blood first if:

• The paper advances hematology as a field: malignant hematology, benign hematology, coagulation biology, platelet function, thrombosis with a hematologic mechanism, or translational blood research
• The natural readership is hematologists and the paper is strongest when written for the blood biology and hematologic disease community
• The work has clear field-wide consequence: results that matter to the broad hematology field, not only one niche within it

Think twice about Blood if:

• The hematology component is incidental to what is fundamentally a cardiovascular or cardiology paper; Blood will redirect this quickly
• The paper is narrowly limited to a single hematologic niche without field-wide relevance; Blood wants manuscripts that matter to the full hematology readership
• The study is preliminary or underpowered; Blood's editorial screen identifies methodological gaps early and the desk-rejection rate on incomplete manuscripts is high

In our pre-submission review work with manuscripts targeting both European Heart Journal and Blood, three patterns generate the most consistent mismatch decisions among the papers we analyze.

Thrombosis papers submitted to EHJ where the mechanism is hematological rather than cardiovascular. The most common mismatch we see is a mechanistic thrombosis paper examining coagulation pathways, platelet biology, or clotting factor function submitted to EHJ because cardiovascular consequences are mentioned. EHJ wants papers where cardiologists are the primary clinical actors. When the mechanism and readership are hematological, EHJ's editorial team redirects the paper to Blood or to Journal of Thrombosis and Haemostasis. This misframe produces a fast desk rejection that the authors typically find surprising.

Blood submissions where the cardiovascular consequence is the primary clinical finding. The reverse pattern also appears regularly. Papers on cardiovascular complications of sickle cell disease, hematologic toxicities after cardiac surgery, or coagulation in heart failure patients are sometimes submitted to Blood when the primary clinical consequence is cardiovascular management. Blood wants papers that change hematology practice or advance blood biology. When the paper is really a cardiovascular medicine paper using a hematologic population, it belongs at a cardiology journal.

Incomplete mechanistic packages submitted to Blood for hematologic novelty alone. Blood's editorial standard requires that mechanistic work be accompanied by enough functional validation to support the claimed biological conclusion. We see papers with novel hematologic findings submitted before the mechanistic story is complete: interesting single-cell sequencing results without functional confirmation, or coagulation pathway work without in-vivo validation. Blood's editorial team makes fast decisions on these, and the desk rejection language typically points to "incomplete mechanistic support" rather than topic mismatch.

SciRev author-reported data confirms that Blood's median time to first decision is typically around 2 to 3 weeks. A EHJ vs. Blood framing and journal-fit check can identify whether your manuscript is correctly framed for the journal you're targeting before you submit.

• European Heart Journal submission guide
• Blood submission guide